OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts have an average recommendation of "Hold" on OKYO based on five ratings (3 buys, 1 hold, 1 sell), with a mean 12‑month price target of $6.33 versus the stock trading around $1.60.
• Institutional activity is limited (about 2.97% ownership), though Renaissance Technologies raised its stake by 235% to 138,000 shares and Citadel and XTX opened small positions.
• OKYO is a clinical‑stage biopharma using Fc‑fusion technology, with lead candidate OK‑101 in Phase 2 for diabetic kidney disease.

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of "Hold" from the five analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $6.3333.

Several brokerages have recently weighed in on OKYO. Piper Sandler began coverage on OKYO Pharma in a report on Friday, February 20th. They issued an "overweight" rating and a $7.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of OKYO Pharma in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OKYO Pharma in a research report on Tuesday, April 21st.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OKYO. Renaissance Technologies LLC lifted its holdings in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company's stock valued at $286,000 after buying an additional 96,800 shares in the last quarter. XTX Topco Ltd bought a new position in OKYO Pharma in the 4th quarter worth about $36,000. Finally, Citadel Advisors LLC bought a new position in OKYO Pharma in the 3rd quarter worth about $31,000. 2.97% of the stock is currently owned by institutional investors.

OKYO Pharma Price Performance

Shares of NASDAQ OKYO opened at $1.60 on Wednesday. OKYO Pharma has a 1 year low of $1.32 and a 1 year high of $3.35. The firm has a 50-day simple moving average of $1.63 and a two-hundred day simple moving average of $1.98.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.